Wolfe Research lifts Abbott Laboratories [ABT] price estimate. Who else is bullish?

Abbott Laboratories [NYSE: ABT] stock went on a downward path that fall over -0.17% on Tuesday, amounting to a one-week price increase of more than 0.21%. The company report on January 18, 2024 at 1:45 PM that Continuing to Lead the Way in Sustainability.

Abbott earns top overall industry score for 11 years, leads in health access on global sustainability benchmark DJSI.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Over the last 12 months, ABT stock rose by 1.05%. The one-year Abbott Laboratories stock forecast points to a potential upside of 5.68. The average equity rating for ABT stock is currently 1.84, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $197.91 billion, with 1.74 billion shares outstanding and 1.72 billion shares in the current float. Compared to the average trading volume of 5.51M shares, ABT stock reached a trading volume of 5033758 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Abbott Laboratories [ABT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABT shares is $120.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABT stock is a recommendation set at 1.84. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wolfe Research have made an estimate for Abbott Laboratories shares, keeping their opinion on the stock as Peer Perform, with their previous recommendation back on July 21, 2023.

The Average True Range (ATR) for Abbott Laboratories is set at 1.48, with the Price to Sales ratio for ABT stock in the period of the last 12 months amounting to 4.95. The Price to Book ratio for the last quarter was 5.28, with the Price to Cash per share for the same quarter was set at 4.06. Price to Free Cash Flow for ABT in the course of the last twelve months was 44.06 with Quick ratio for the last quarter at 1.23.

ABT Stock Performance Analysis:

Abbott Laboratories [ABT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.21. With this latest performance, ABT shares gained by 6.15% in over the last four-week period, additionally sinking by -0.54% over the last 6 months – not to mention a rise of 1.05% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABT stock in for the last two-week period is set at 69.77, with the RSI for the last a single of trading hit 67.57, and the three-weeks RSI is set at 69.27 for Abbott Laboratories [ABT]. The present Moving Average for the last 50 days of trading for this stock 106.74, while it was recorded at 114.17 for the last single week of trading, and 104.52 for the last 200 days.

Insight into Abbott Laboratories Fundamentals:

Abbott Laboratories’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.23 and a Current Ratio set at 1.74.

ABT Stock EPS

With the latest financial reports released by the company, Abbott Laboratories posted 1.03/share EPS, while the average EPS was predicted by analysts to be reported at 0.92/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbott Laboratories go to -2.00%.

Abbott Laboratories [ABT] Institutonal Ownership Details

The top three institutional holders of ABT stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in ABT stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in ABT stock with ownership which is approximately 5.8325%.